Vitamin A, Its Receptors and Asthma

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Selina Gierer, D.O., University of Kansas
ClinicalTrials.gov Identifier:
NCT00628329
First received: February 26, 2008
Last updated: May 3, 2012
Last verified: May 2012
  Purpose

We wish to understand the association of Vitamin A serum levels and Vitamin A receptor number and responsiveness in asthmatics. We believe that Vitamin A receptors may be less prevalent in asthmatics and their responsiveness decreased.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Vitamin A, Its Receptors and Asthma: Vitamin A Levels in Serum and Expression and Responsiveness of Vitamin A Receptors in Circulating Mononuclear Cells of Asthmatics

Resource links provided by NLM:


Further study details as provided by University of Kansas:

Primary Outcome Measures:
  • Retinol levels in blood, flow cytometric study of the RXRRAR receptors before and after addition of ATRA, 9-cis-RA and steroid [ Time Frame: 2-4 weeks after blood sample drawn ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum without DNA, cells with DNA


Enrollment: 0
Study Start Date: May 2008
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)

Detailed Description:

We wish to define the association of asthma, vitamin A serum levels and vitamin A receptor number and responsiveness on circulating mononuclear cells. Asthma is a complex, heterogenous and often debilitating and potentially deadly disease. The causes for asthma are many, with susceptibility and resistance to treatment is poorly understood. Ultimately, looking at this disease from another angle such as the role of Vitamin A and/or receptors can help us learn more about the pathophysiology and treatment of asthma.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Male or female Age 18-64

Criteria

Inclusion Criteria:

  • Patients with previously diagnosed asthma on inhaled corticosteroids, systemic steroids and/or long acting beta agonist (for a period of 6 mo to 5 years)
  • Age 18-64
  • Male or female

Exclusion Criteria:

  • Children under age 18
  • Adults 65 or older
  • Patients with COPD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00628329

Locations
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
University of Kansas
Investigators
Principal Investigator: Daniel Stechschulte, MD University of Kansas
  More Information

No publications provided

Responsible Party: Selina Gierer, D.O., Assistant Professor, University of Kansas
ClinicalTrials.gov Identifier: NCT00628329     History of Changes
Other Study ID Numbers: 11213
Study First Received: February 26, 2008
Last Updated: May 3, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Kansas:
asthma, retinol, cis-retinoic acid

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Vitamin A
Vitamins
Retinol palmitate
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 26, 2014